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University of Michigan, Ann Arbor, MI, 2 Cedars-Sinai Medical Center, Los Angeles, CA Background: It may be challenging to distinguish low-flow low-gradient (LFLG) severe aortic stenosis (AS) from pseudo-severe AS, underestimation normal-flow high-gradient (NFHG) AS, or inaccurate effective orifice area (EOA) on transthoracic echocardiography (TTE). We evaluated changes in classification of AS by left/right heart catheterization (LHC) over TTE findings alone. Methods: We examined 144 consecutive individuals with severe AS on TTE (EOA <1.0 cm2 or indexed EOA <0.6 cm 2 /m 2 ) and LHC within 2 months referred for possible transcatheter aortic valve implantation (TAVI), and after exclusion of patients with >mild tricuspid regurgitation (n¼27), subaortic obstruction (n¼3) or non-diagnostic studies (n¼6). We evaluated the prevalence and hemodynamic findings of NFHG (mean gradient >40 mmHg or peak velocity >4.0 m/sec) and LFLG severe AS on TTE (mean gradient 40 mmHg and peak velocity 4.0 m/sec), and assessed the frequency in which LHC reclassified AS type. Results: Mean age was 78.9AE8.8 years, and 58.3% were male. TTE observed a high mean gradient in 36% (52/144) of patients, while a high peak velocity was noted in 44% (63/144). LHC observed a high gradient in 59% (85/144) of individuals. Overall, TTE identified NFHG and potential LFLG severe AS in 46% (66/144) and 54% (78/ 144) of patients, respectively. In the 78 patients with potential LFLG severe AS by TTE, LHC reported a mean gradient >40 mmHg in 41% (32/78), consistent with TTE underestimation of gradients; in an additional 10% (8/78), LHC reported an EOA !1.0 cm 2 , suggesting overestimation of AS severity on TTE. In comparison to TTE alone, the addition of LHC findings reduced the proportion of patients with potential LFLG severe AS from 54% (78/144) Background: TAVI represents an emerging technology that is nowadays widely used for the treatment of aortic-valve disease in high-risk patients. However, paravalvular leakage (PVL) still represents a major problem and was recently shown to be associated with increased mortality and morbidity. This study evaluates the impact of CT based aortic-valve calcification and its distribution on the post-procedural occurrence of PVL. Methods: From May 2008 to December 2012 a total of 369 patients were scheduled for the treatment of aortic stenosis with a TAVI procedure either using a CoreValve-Medtronic (n¼198), Edwards-SAPIEN (n¼164), Symetis-Acurate (n¼2) and Medtronic-Engager prosthesis (n¼5). Of these, 260 patients with a mean logistic EuroSCORE I of 19.3AE12% had a preoperative CT-Scan and were included in this study. AVCS was measured in mg and mm3 using a method analogous to the Agatston calcium scoring of coronary arteries. The image data were analyzed separately to determine the degree of calcification for each cusp and commissure. The occurrence of intra-or post-procedural PVL was assessed by echocardiography and correlated to the calcium degree and distribution. Results: TAVI was successfully performed in 254 Patients (97.7%). A new Pacemaker Implantation was observed in 22.4% (n¼57) of patients and MACE (Myocardial Infarction, Stroke, major vascular complication, Death) occurred in 11.4% (n¼29) of all cases. The mean hospital length of stay was 11.3 AE 8.3 days. There was a statistically relevant difference in AVCS between Groups when correlating to the occurrence of postinterventional PVL Grade*0-1 (550.4 AE 377.2 mg, n¼164) and Grade 2 (755.6 AE 470.6 mg, n¼78, p<0.001) or Grade 3 (825 AE 460.8 mg, n¼12, p<0.05). There was no correlation between a new pacemaker implantation and AVCS. Conclusions: This study highlights the significant correlation between the degree of calcification and the occurrence of post-interventional paravalvular leakage after TAVI procedure. Thus, preoperative AVCS calculation may represents an important predictor for PVL and may be added to the routine list of parameters for CT planning before TAVI. *PVL Grade 0 -none; 1 -minimal; 2 -mild; 3moderate
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